Healius

HLS.ASX

Health Care

Pathology company.

Market Data

Price

$0.340

-0.0%

Market Cap

$254.2M

P/E Ratio

-100000.0x

EPS

$-0.756

Div. Yield

0.00%

52-Week Change

-0.5%

Recent Announcements

29 May 2026 Sph Neutral

Ceasing to be a substantial holder from MQG

MQG ceased to be a substantial holder.

27 May 2026 Date Announcement Neutral

Earnings Release - 19 August 2026

Upcoming earnings release expected 19 August 2026 (from Yahoo Finance (confirmed))

26 May 2026 Sph Neutral

Becoming a substantial holder from MQG

MQG became a substantial holder (5.06%).

22 May 2026 Sph Neutral

Ceasing to be a substantial holder from MQG

MQG ceased to be a substantial holder.

21 May 2026 Sph Neutral

Becoming a substantial holder from MQG

MQG became a substantial holder (5.06%).

20 May 2026 Sph Neutral

Ceasing to be a substantial holder from MQG

MQG ceased to be a substantial holder.

18 May 2026 Sph Neutral

Ceasing to be a substantial holder

Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) ceased to be a substantial holder.

15 May 2026 Sph Neutral

Becoming a substantial holder

Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) became a substantial holder (5.0701%).

13 May 2026 Guidance Neutral

FY26 trading update and strategic review of assets

Healius Limited (ASX: HLS) released a FY2026 trading update projecting Group Underlying EBITDA of $259-264m and EBIT of $30-35m, while announcing a strategic review and potential sale of its Agilex Biolabs subsidiary with assistance from UBS Securities, citing unsolicited approaches from credible parties.

16 Apr 2026 Sph Neutral

Ceasing to be a substantial holder

Dimensional Entities ceased to be a substantial holder.

Get real-time alerts for HLS

Receive AI-powered earnings summaries and instant notifications when Healius releases results.